FEATURED SLIDESHOW
Who Is The Worst CEO?Mad Money needed new inductees for its
Wall of Shame, so we asked viewers for
nominations.
RECENT POSTS
- Lightning Round: CVS Caremark, Devon Energy, Tyson Foods and More
- Lightning Round OT: Ford, NewAlliance Bancshares and More
- Why You Should Speculate on Stocks
- Next Week’s Top IPO
- Cramer: 5 Earnings Reports to Watch Next Week
- More Americans Lighting Up? Buy This Stock
- What Happened to Cypress Semi?
- Lightning Round: Raytheon, Salesforce.com, Pepsi and More
- Lightning Round OT: Apache, Brocade, Allergan and More
- Cramer Goes One-on-One With Costco CEO
MAD MONEY FEATURES
PODCASTSWatch the Lightning Round whenever and wherever you want.
OFFICIAL MAD MONEY WIDGETGrab this all-in-one application and get recaps of the show sent right to your desktop or blog.
CRAMER'S SOUNDBOARDAdmit it: You’ve always wanted to hit the “They know nothing!” button. Here’s your chance.
CRAMER QUICK PICSCheck out the Mad Money host on set, back to school, behind the scenes and more.
VIDEOSGet all your favorite Cramer clips right here.
SHOP FOR MAD MERCHANDISEBuy Cramer books, bobbleheads and other Mad Money merchandise.
RING TONESPick up the phone! It’s Cramer! New Mad Money sounds for your cell phone.
TEXT MESSAGE ALERTMad Money’s mobile. Get show highlights sent to your phone.
Text Size 
 |
Case in point: A July 26 New York Times story reported that Type 2 diabetes in American children is growing at a rate of 10% to 15% a year. From 2001 to 2007, prescriptions for these kids rose 151%. Never morbid, but always astute, Cramer knew there was a way to play this epidemic-like trend.
Enter Novo Nordisk [NVO
Loading...
()
], the top insulin producer in the world with a 52% market share.
Novo Nordisk has a diabetes 2 and weight-loss drug – 30% of American kids are overweight – called Liraglutide that’s expected to outperform Amylin Pharmaceutical’s [AMLN
Loading...
()
] Byetta, a similar treatment. Cramer’s betting that Food & Drug Administration approval will be a huge catalyst for Novo Nordisk, and he wants investors in before the announcement. (The company’s capital markets day in September is another catalyst investors should anticipate.)
Liraglutide is a once-a-day injection compared to Byetta’s two shots a day. And Liraglutide has proved better at controlling blood sugar levels, just as capable at inducing weight loss, and carried it with it less side effects than Byetta.
Liraglutide has been tested for weight loss on non-diabetics as well. Compared to top weight-loss drug Xenical, patients who used NVO’s treatment lost about 10 pounds more. And Liraglutide also erased any pre-diabetes signs in 80% of the patients who took this medicine. Barack Obama, take notice – here’s the preventative healthcare you talk so much about.
The market for Liraglutide and Byetta – and they are the only two drugs in the field – is expected to hit $4.4 billion by 2012. it was only $636 million last year. And with diagnosis rates on the rise, that market could get bigger.
Plus, once Novo Nordisk gets approval, which his expected by Q2 2009, doctors who are already used to prescribing Byetta can start to recommend Liraglutide for off-label uses like weight loss and preventative care as well.
Byetta sales grew about 570% for Amylin from its first to second year, so Cramer doubts NVO will be trading at $63 and change for long. He said $70 in the short term is more likely, and if Liraglutide takes off as expected, who knows how much higher.
Questions for Cramer?
Questions, comments, suggestions for the Mad Money website?
Data is a real-time snapshot *Data is delayed at least 15 minutes